Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Por:
Blauvelt, A, Langley, RG, Lebwohl, M, Strober, B, Warren, RB, Puig, L, Morita, A, Gordon, KB, Fernandez-Peña, P, Kavanagh, S, Pinto, JML, Lambert, J, Hoepken, B, Deherder, D, Cross, N, Thaçi, D
Publicada:
1 sep 2025
Ahead of Print:
1 ago 2025
Resumen:
Background: Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. Objective: To report 4-year end-of-study bimekizumab efficacy and safety in patients with moderate to severe psoriasis. Methods: Data were pooled from 3 phase 3 trials (BE VIVID, BE READY, and BE SURE) and their open-label extension (OLE; BE BRIGHT). Efficacy is reported for patients who received bimekizumab continuously from baseline into the OLE. Safety is reported for patients who received $1 bimekizumab dose. Results: Seven hundred seventy-one patients received bimekizumab from baseline into the OLE. A high proportion achieved complete skin clearance (100% improvement from baseline in Psoriasis Area and Severity Index) at Week 52 (76.2%) and maintained this to Week 196 (64. 7%). The rate of treatment-emergent adverse events over 4 years was 169.8/100 patient-years (N = 1495) and did not increase with longer exposure. The most common treatment-emergent adverse events were nasopharyngitis, oral candidiasis, and upper respiratory tract infection, consistent with bimekizumab's known safety profile. Limitations: Eligibility criteria and ethnic representation. Conclusion: Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 4 years, making bimekizumab an effective, rapid, and durable long-term treatment option.
Filiaciones:
Blauvelt, A:
Blauvelt Consulting LLC, Annapolis, MD USA
Langley, RG:
Dalhousie Univ, Dept Med, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
Lebwohl, M:
Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
Strober, B:
Yale Univ, Dept Dermatol, New Haven, CT USA
Cent Connecticut Dermatol Res, Cromwell, CT USA
Warren, RB:
NHS Fdn Trust, Dermatol Ctr, Northern Care Alliance, Manchester, England
Univ Manchester, Manchester Acad Hlth Sci Ctr, Div Musculoskeletal & Dermatol Sci, Manchester, England
Puig, L:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Spain
Morita, A:
Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Japan
Gordon, KB:
Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI USA
Fernandez-Peña, P:
Univ Sydney, Westmead Hosp, Dept Dermatol, Westmead, NSW, Australia
Kavanagh, S:
UCB, Morrisville, NC USA
Pinto, JML:
UCB, Madrid, Spain
Lambert, J:
UCB, Colombes, France
Hoepken, B:
UCB, Monheim Am Rhein, Germany
Deherder, D:
UCB, Braine Lalleud, Belgium
Cross, N:
UCB, Morrisville, NC USA
Thaçi, D:
Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
hybrid
|